UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ten common pitfalls in the evaluation of patients with hyponatremia

European journal of internal medicine, 2016-04, Vol.29, p.22-25

2016

Volltextzugriff (PDF)

SGLT2 inhibitors and the kidney: Effects and mechanisms

Diabetes & metabolic syndrome clinical research & reviews, 2018-11, Vol.12 (6), p.1117-1123

2018

Volltextzugriff (PDF)

Statin-associated adverse effects beyond muscle and liver toxicity

Atherosclerosis, 2007-11, Vol.195 (1), p.7-16

2007

Volltextzugriff (PDF)

Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition

Current vascular pharmacology, 2017-01, Vol.15 (2), p.96-102

2017

Volltextzugriff (PDF)

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome

Atherosclerosis, 2007-08, Vol.193 (2), p.428-437

2007

Volltextzugriff (PDF)

Effects of hormonal treatment on lipids in patients with cancer

Cancer treatment reviews, 2009-04, Vol.35 (2), p.175-184

2009

Volltextzugriff (PDF)

Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile

Nutrition, metabolism, and cardiovascular diseases, 2013-04, Vol.23 (4), p.330-336

2013

Volltextzugriff (PDF)

Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2 ) activity in healthy obese women

Nutrition, metabolism, and cardiovascular diseases, 2008-09, Vol.18 (7), p.477-482

2008

Volltextzugriff (PDF)

Effects of sibutramine and orlistat on mood in obese and overweight subjects: A randomised study

Nutrition, metabolism, and cardiovascular diseases, 2008-03, Vol.18 (3), p.207-210

2008

Volltextzugriff (PDF)

SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms

Diabetes & metabolic syndrome clinical research & reviews, 2018-01, Vol.12 (1), p.59-63

2018

Volltextzugriff (PDF)

Serum PCSK9 levels are increased in obese subjects and negatively correlated with a mediterranean diet score

Atherosclerosis, 2018-08, Vol.275, p.e251-e252

2018

Volltextzugriff (PDF)

effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome

Diabetes, obesity & metabolism, 2008-06, Vol.10 (6), p.476-483

2008

Volltextzugriff (PDF)

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A 2 in obese patients with metabolic syndrome

Atherosclerosis, 2007, Vol.193 (2), p.428-437

2007

Volltextzugriff (PDF)

Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A 2 (Lp-PLA 2) activity in healthy obese women

Nutrition, metabolism, and cardiovascular diseases, 2008, Vol.18 (7), p.477-482

2008

Volltextzugriff (PDF)

P325 THE EFFECTS OF HYPOLIPIDEMIC TREATMENT ON LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN PATIENTS WITH MIXED HYPERLIPIDEMIA

Atherosclerosis. Supplements, 2010-06, Vol.11 (2), p.86-86

2010

Volltextzugriff (PDF)

MS46 THE EFFECTS OF HYPOLIPIDEMIC REGIMEN ON LOW DENSITY LIPOPROTEIN (LDL) PHENOTYPE IN PATIENTS WITH MIXED HYPERLIPIDEMIA

Atherosclerosis. Supplements, 2010-06, Vol.11 (2), p.119-119

2010

Volltextzugriff (PDF)

EFFECTS OF FENOFIBRATE AND ORLISTAT, ALONE OR IN COMBINATION, ON PLASMA VISFATIN LEVELS IN SUBJECTS WITH METABOLIC SYNDROME

Atherosclerosis. Supplements, 2008-05, Vol.9 (1), p.133-134

2008

Volltextzugriff (PDF)

W16-P-028 Effects of combination of orlistat and micronised fenofibrate on lipid profile in overweight and obese patients with metabolic syndrome

Atherosclerosis. Supplements, 2005-04, Vol.6 (1), p.107-107

2005

Volltextzugriff (PDF)

T04-P-016 Plasma PAF-Acetylhydrolase (LP-PLA2) activity as a marker of small-dense LDL in subjects at median cardiovascular risk

Atherosclerosis. Supplements, 2005-04, Vol.6 (1), p.155-156

2005

Volltextzugriff (PDF)

PO21-642 HYPERTRIGLYCERIDAEMIC WAIST PHENOTYPE DEFINITIONS AND PREVALENT METABOLIC TRIAD IN WOMEN

Atherosclerosis. Supplements, 2007-06, Vol.8 (1), p.173-173

2007

Volltextzugriff (PDF)

PO23-773 PHENOTYPE DETERMINANTS OF THE TRIGLYCERIDES LOWERING EFFECT OF ROSUVASTATIN

Atherosclerosis. Supplements, 2007-06, Vol.8 (1), p.206-206

2007

Volltextzugriff (PDF)

EFFECTS OF ORLISTAT AND FENOFIBRATE, ALONE OR IN COMBINATION, ON PLASMA APOLIPOPROTEIN C-II AND C-III LEVELS IN METABOLIC SYNDROME PATIENTS

Atherosclerosis. Supplements, 2008-05, Vol.9 (1), p.191-191

2008

Volltextzugriff (PDF)

We-P14:382 The effects of weight loss on LP-PLA2 activity and low density lipoprotein (LDL) phenotype in obese women

Atherosclerosis. Supplements, 2006, Vol.7 (3), p.431-431

2006

Volltextzugriff (PDF)

Th-P16:271 Effects of orlistat and fenofibrate combination on LDL phenotype in overweight and obese patients with metabolic syndrome the fenorli study

Atherosclerosis. Supplements, 2006, Vol.7 (3), p.553-553

2006

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(12)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ten common pitfalls in the evaluation of patients with hyponatremia

SGLT2 inhibitors and the kidney: Effects and mechanisms

Statin-associated adverse effects beyond muscle and liver toxicity

Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome

Effects of hormonal treatment on lipids in patients with cancer

Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile

Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2 ) activity in healthy obese women

Effects of sibutramine and orlistat on mood in obese and overweight subjects: A randomised study

SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms

Serum PCSK9 levels are increased in obese subjects and negatively correlated with a mediterranean diet score

effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome

The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A 2 in obese patients with metabolic syndrome

Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A 2 (Lp-PLA 2) activity in healthy obese women

P325 THE EFFECTS OF HYPOLIPIDEMIC TREATMENT ON LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN PATIENTS WITH MIXED HYPERLIPIDEMIA

MS46 THE EFFECTS OF HYPOLIPIDEMIC REGIMEN ON LOW DENSITY LIPOPROTEIN (LDL) PHENOTYPE IN PATIENTS WITH MIXED HYPERLIPIDEMIA

EFFECTS OF FENOFIBRATE AND ORLISTAT, ALONE OR IN COMBINATION, ON PLASMA VISFATIN LEVELS IN SUBJECTS WITH METABOLIC SYNDROME

W16-P-028 Effects of combination of orlistat and micronised fenofibrate on lipid profile in overweight and obese patients with metabolic syndrome

T04-P-016 Plasma PAF-Acetylhydrolase (LP-PLA2) activity as a marker of small-dense LDL in subjects at median cardiovascular risk

PO21-642 HYPERTRIGLYCERIDAEMIC WAIST PHENOTYPE DEFINITIONS AND PREVALENT METABOLIC TRIAD IN WOMEN

PO23-773 PHENOTYPE DETERMINANTS OF THE TRIGLYCERIDES LOWERING EFFECT OF ROSUVASTATIN

EFFECTS OF ORLISTAT AND FENOFIBRATE, ALONE OR IN COMBINATION, ON PLASMA APOLIPOPROTEIN C-II AND C-III LEVELS IN METABOLIC SYNDROME PATIENTS

We-P14:382 The effects of weight loss on LP-PLA2 activity and low density lipoprotein (LDL) phenotype in obese women

Th-P16:271 Effects of orlistat and fenofibrate combination on LDL phenotype in overweight and obese patients with metabolic syndrome the fenorli study

Suchergebnisse filtern